Since HN1, AR, and EGFR have been reported as highly expressed genes in prostate adenocarcinoma and stimulation of AR without androgens gives a survival advantage to prostate cancer cells post-androgen ablation therapy, HN1 could be placed at a crossroads in intervention therapies that involve targeting AR in cancers’ refractory to hormones [12]. The gene discussed is JPT1; the disease is prostate adenocarcinoma.